Investor Presentaiton

55 59 Kaplan-Meier Survivor Function 1.0 GBM-001 Progression-Free Survival at Six Months (PFS6) Kaplan-Meier Analysis of Time to Confirmed Progression by Biopsy or RANO Cohort A: MGMT Unmethylated (mITT): All Available Follow-Up 0.8- 06- 0.4 0.2 0.0 First Quartile: 170 Days Median: Not Evaluable 95% CI: (64) 95% CI Not Evaluable Third Quartile: Not Evaluable 95% CI Not Evaluable 3031 29 3 15 # No at Risk 5 D No of Events T 0 60 120 180 240 300 360 420 Exposure in Days Kaplan-Meier Survivor Function Kaplan-Meier Analysis of Time to Confirmed Progression by Biopsy or RANO Cohort B: MGMT Methylated or Indeterminate (mITT): All Available Follow-Up 1.0 0.8- 0.6- 0.4- 02- 0.0- 20 First Quartile: 184 Days Median: Not Evaluable 95% CI: (40, ) 95% CI: (184,) Third Quartile: Not Evaluable 95% CI Not Evaluable 17 15 Kaplan-Meier Survivor Function 1.0- Kaplan-Meier Analysis of Time to Confirmed Progression by Biopsy or RANO Combined Cohorts A & B (mITT): All Available Follow-Up 0.8- 0.6- 0.4- 0.2- 0.0 No at Risk $2 3 No of Events 240 300 360 e 2 о 60 120 180 Exposure in Days Number of events and number of subjects at risk calculated at 3 monthly internals Data as of 24 October 2018 including reports on s First Quartile: 184 Days Median: Not Evaluable 95% CI: (120) 95% CI Not Evaluable Third Quartile: Not Evaluable 95% CI Not Evaluable 15 No at Risk No of Events 0 60 120 180 240 300 360 Exposure in Days Data as of 24 October 2018 dung porn se Cohort N Subjects N Event-free Subjects PFS6 (%) 95% CI Lower Bound 95% CI Upper Bound Cohort A (MGMT Unmethylated) 32 24 75 56.6 88.5 Cohort B (MGMT Methylated) 20 16 80 56.3 94.3 Both Cohorts Combined 52 40 77 63.2 87.5 Confirmed PD (RANO) = confirmation by consecutive PD scan ≥4 weeks from original PD event, or progressed according to biopsy surgery. Subjects who terminated for any reason prior to 6 months other than PD included as confirmed progressive events, including two (2) subjects in Cohort B who came off-study at week three (3), and declined long-term follow-up. Note: subjects with time to events longer than 6 months included; subjects have different time on study durations. INOVIO POWERING DNA MEDICINES

View entire presentation